This document provides guidelines on the use of iodine-based and gadolinium-based contrast agents. It discusses acute and late adverse reactions to iodine-based agents and risks for patients taking metformin. It also covers use in pregnancy/lactation and measures to reduce contrast-induced nephrotoxicity and risks of nephrogenic systemic fibrosis from gadolinium agents. The EMA suspended marketing of some linear gadolinium agents but macrocyclic agents remain available given lower risks of releasing gadolinium. Healthcare professionals should use the lowest necessary doses of contrast agents only when essential for diagnosis.
Presentation is highlighting the integration of different modalities in the management of locally advanced and metastatic prostate cancer pointing to the proven values of adding chemotherapy. A special note has been made to oligometastatic disease.
Changing landscape in the treatment of advanced prostate cancer Alok Gupta
This presentation describes how the treatment of stage 4 prostate cancer has improved over last 100 years. This was presented at URO ONCOLOGY UPDATE meeting of Delhi Urological Society on 18th March 2017
SEMINAR PRESENTATION ON CONTRAST INDUCED NEPHROPATHY BY PHARM D STUDENT
IT INCLUDES COMPLETE OVERVIEW OF THE TOPIC CIN.
POST CONTRAST ACUTE KIDNEY INJURY( PC-AKI) WITH TREATMENT AND MANAGEMENT.
Presentation is highlighting the integration of different modalities in the management of locally advanced and metastatic prostate cancer pointing to the proven values of adding chemotherapy. A special note has been made to oligometastatic disease.
Changing landscape in the treatment of advanced prostate cancer Alok Gupta
This presentation describes how the treatment of stage 4 prostate cancer has improved over last 100 years. This was presented at URO ONCOLOGY UPDATE meeting of Delhi Urological Society on 18th March 2017
SEMINAR PRESENTATION ON CONTRAST INDUCED NEPHROPATHY BY PHARM D STUDENT
IT INCLUDES COMPLETE OVERVIEW OF THE TOPIC CIN.
POST CONTRAST ACUTE KIDNEY INJURY( PC-AKI) WITH TREATMENT AND MANAGEMENT.
Adrenal tumor, classification, management - easy explanationSwatilekha Das
Adrenal tumor- topic for B.Sc Nursing Students, GNM Students
definition
classification
clinical manifestations
treatment
easy explanation for nursing students
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Guid lines on iodine and gabollinium contrast prof.tarek el diasty
1. Prof. Tarek El-Diasty
Radiology Department
Urology & Nephrology Center - Mansoura University
GUIDELINES ON IODINE-BASED
AND GADOLINIUM-BASED
CONTRAST AGENTS
4. Acute Adverse Reactions
• Definition: An adverse reaction which
occurs within 1 hour of contrast medium
injection.
• The risk of an acute reaction to a gadolinium-
based contrast agent is significantly lower than
the risk with an iodine-based contrast agent, but
severe reactions to gadolinium-based contrast
media may occur.
5. To reduce the risk of an acute reaction
- For ALL patients:
• Use a non-ionic contrast medium.
• Keep the patient in the radiology department
for 30 min after contrast medium injection.
• Have the drugs and equipment for
resuscitation readily available.
6. Risk factors for acute reactions
- Patients-related:
• Previous moderate or severe acute reaction to an
iodine-based contrast agent.
• Asthma.
• Allergy requiring medical treatment.
- Contrast-related:
• High osmolality ionic contrast media.
7. For patients at increased risk
• Consider an alternative test not requiring
an iodine-based contrast agent.
• Use a different iodine-based agent for
previous reactors to contrast medium.
8. For patients at increased risk
• Consider the use of premedication. Clinical
evidence of the effectiveness of
premedication is limited. If used, a suitable
premedication regime is prednisolone 30 mg
(or methylprednisolone 32 mg) orally given
12 and 2 hours before contrast medium.
9. Management
• First line emergency drugs and
instruments which should be in the
examination room:
- Oxygen
- Adrenaline 1:1,000
- Atropine
- I.V. Fluids; normal saline or Ringer’s solution
- Anti-convulsive drugs (diazepam)
- Sphygmomanometer
- One-way mouth “breather” apparatus
10. Late adverse reactions
• A late adverse reaction to intravascular iodine-
based contrast medium is defined as a reaction
which occurs 1 h to 1 week after contrast medium
injection.
• Skin reactions similar in type to other drug induced
eruptions. Maculopapular rashes, erythema, swelling
and pruritus are most common. Most skin reactions
are mild to moderate and self-limiting.
11. Risk of Iodine-based CM in
Patients Taking Metformin
Lactic Acidosis
Metformin is excreted unchanged in the
urine. In the presence of renal failure,
either pre-existing or induced by iodinated
CM, metformin may accumulate in
sufficient amounts to cause lactic acidosis.
N.B. Metformin does not cause RF.
12. Risk of Iodine-based CM in
Patients Taking Metformin
- If eGFR is greater than 60 ml/min, the pt
can continue to take metformin.
- If eGFR is between 30 and 60 ml/min (or
serum creatinine is raised) stop metformin
48 hr before CM adminstration and remain
off metformin 48 hr after CM.
13. Risk of Iodine-based CM in
Patients Taking Metformin
- Restart metformin if S creatinine is
unchanged 48 hr after CM adminstration.
- If eGFR is less than 30 ml/min metformin
is not approved in most countries and
iodinated CM should be avoided if possible.
14. IBCA - PREGNANCY
• In exceptional circumstances, when
radiographic examination is essential,
iodine- based contrast media may be given
to the pregnant female.
• Following administration of iodine-based
agents to the mother during pregnancy,
thyroid function should be checked in the
neonate during the first week.
15. GBCA - PREGNANCY
• When there is a very strong indication for
enhanced MR, the smallest possible dose of
one of the most stable gadolinium contrast
agents may be given to the pregnant
female.
• Following administration of gadolinium-
based agents to the mother during
pregnancy, no neonatal tests are necessary.
16. IBCA - LACTATION
• Breast feeding may be continued
normally when iodine-based agents
are given to the mother.
17. GBCA - LACTATION
• Breast feeding should be avoided for 24
hours after contrast medium particularly
if high risk agents are used.
18. PREGNANT OR LACTATING
MOTHER WITH RENAL
IMPAIRMENT
• Do not administer iodine-based or
gadolinium-based contrast agents.
20. GBCA - Nephrotoxicity
• The risk of Gd-induced nephrotoxicity is very low
when GBCAs are used in approved doses.
• GBCA should not be used for radiographic
examinations.
• GBCAs are more nephrotoxic than iodinated CAs in
equivalent x-ray attenuation doses.
22. Non-contrast MRA
Breath-hold Steady State Free percission (SSFP
MRA) can be performed as the first line MRA
technique to rule out RAS in any patient felt to be
at risk of NSF or having any other
contraindication to gadolinium contrast.
SSFP MRA is not yet recommended for
pretransplant evaluation,as the limited acquired
imaging volume may miss important accessory
renal arteries.
23. Contrast Induced
Nephrotoxicity (CIN)
Definition
CIN is a condition in which an impairment in
renal function (an increase in serum
creatinine by more than 25% ”0.5 mg/dl”)
occurs within 3 days following
intravascular administration of CM in the
absence of an alternative etiology.
24. Contrast Induced
Nephrotoxicity (CIN)
Patients at high risk
The patients at highest risk for developing
CIN are those with pre-existing renal
impairment (>132 mmol/l) particularly when
the reduction in renal function is secondary
to diabetic nephropathy
25. Measures to Reduce CIN
Volume expansion, hydration with intravenous
administration of normal saline solution (NaCl
0.9%) or half strength saline solution (NaCl
0.45%), infusion of mannitol, administration
of atrial na triuretic peptide, loop diuretics,
calcium antagonists, theophylline, dopamine,
the dopamine-1 receptor antagonist
fenoldopam, acetylcysteine.
26. Measures to Reduce CIN
Iodinated CM
No pharmacological manipulation
(renal vasodilators, receptor
antagonists of endogenous vasoactive
mediators or cytoprotective drugs)
has yet been shown to offer
consistent protection against CIN.
27. Measures to Reduce CIN
Iodinated CM
rapidly after contrastHaemodialysis
administration, haemofiltration during and
after contrast administration, an injection
of a small volume of CM, and avoiding short
intervals (<48 h) between procedures
requiring intravascular administration of
CM.
28. Measures to Reduce CIN
Iodinated CM
- Use of low osmolar non-ionic contrast
media instead of high osmolar ionic CM.
- Use of iso-osmolar CM instead of low
osmolar CM.
- ? gadolinium-based CM instead of
iodine-based CM for radiography ,
angiography and CT
29. Of all these measures, extracellular
volume expansion and use of low or iso-
osmolar CM have been found
systematically to be most effective.
30. Measures to Reduce CIN
Gd CM
• MR examinations:
The risk of CIN is very low when Gd CM are
used in approved doses.
• Radiographic examinations:
GBCA should NOT be used for radiographic
examinations in pts with renal impairment.
31. Measures to Reduce CIN
Gd CM
All CM can be removed by hemodialysis and
peritoneal dialysis.
There is NO evidence that hemodialysis
protects pts with impaired renal function
from CIN or NSF.
32. Recommendation
In patients with risk factors, one
should not (i) give high osmolar CM;
(ii) administer large doses of
contrast media;
(iii) administer mannitol and
diuretics, particularly loop diuretics;
and (iv) perform multiple studies with
CM within a short period of time.
33. Recommendation
It is of importance that (i) one makes
sure that the patient is well hydrated [give
at least 100 ml, orally (e.g. soft drinks) or
intravenously (normal saline) depending on
the clinical situation, per hour starting 4 h
before to 24 h after contrast
administration; in warm areas increase the
fluid volume];
34. Recommendation
(ii) low or iso-osmolar CM are used;
(iii) administration of nephrotoxic
drugs is stopped for at least 24 h;
(iv) alternative imaging techniques,
which do not require the administration
of iodinated CM, are considered.
35. Nephrogenic Systemic Fibrosis
- The link between NSF and Gd based contrast
agents was only recognized in 2006.
- Onst: from day of exposure up to 2-3 months.
-Thickened skin and S.C. tissues ‘woody texture’ ;
fibrosis of internal organs (ms.diaphragm, heart,
liver, lung).
- Results: contractures, cachexia, death in a
proportion of patients.
36. NSF - Skin lesions
Prince et al., RadioGraphics 2009; 29:1565–1574
38. Nephrogenic Systemic Fibrosis
• Although many cases are mild and limited
to dermatologic manifestations, an
estimated 5% of cases have a more
fulminant course resulting in death.
39. Nephrogenic Systemic Fibrosis
-The least stable agents may trigger
the development of nephrogenic
systemic fibrosis (NSF) in renal
failure patients.
40. Nephrogenic Systemic Fibrosis
Patients
At higher Risk:
- Pts with CKD 4 and 5 (GFR < 30 ml / min).
- Pts on dialysis.
- Pts with reduced renal function who have had or
are waiting liver transplantation.
41. Nephrogenic Systemic Fibrosis
Patients
At lower Risk:
- Pts with CKD 3 (GFR = 30 - 59 ml / min).
Children under 1 year, because their immature
kidneys.
Not at Risk:
Pts with normal renal function.
42. Nephrogenic Systemic Fibrosis - GBCA
• The least stable agents may trigger
the development of nephrogenic
systemic fibrosis (NSF) in renal
failure patients.
43.
44. Information for patients
• Gadolinium contrast agents are essential for
diagnosing a wide range of life-threatening and
debilitating diseases.
• If you need a scan with a gadolinium contrast
agent to help in your treatment, your doctor will
use the lowest dose required for a clear image.
• If you have any questions about your scan, speak
to your doctor.
45. Information for patients
• It is known that small amounts of gadolinium
may remain in the brain after a scan with
these agents, although there is currently
no evidence that these small amounts cause
any harm.
46. Information for healthcare
professionals
•
has beendeposition in the brainGadolinium•
confirmed by mass spectrometry and
increases in signal intensity in brain tissue.
-in vitro and non, as well asstability• Data on
clinical studies, show that linear gadolinium
agents release gadolinium from to a greater
extent than macrocyclic agents.
47. Information for healthcare
professionals
• No adverse neurological effects, such as
cognitive or movement disorders, have
been attributed to gadolinium deposition in
the brain with any gadolinium agents.
48. Unenhanced T1-weighted MR images of the typical finding of
hyperintensities in the Dentate Nucleus “DN” (arrows).
Images were acquired (a) before and (b) after six administrations of
macrocyclic GBCA and (c) before and (d) after six administrations of
linear GBCA.
Radbruch et al. Radiology: 2015; Volume 275: Number 3
49. Information for healthcare
professionals
• The marketing authorisations for the
intravenous linear agents gadodiamide and
gadoversetamide, as well as the
intravenous formulation of the linear agent
gadopentetic acid, are being suspended in
EU.
51. acidgadoxetic–Two intravenous linear agents•
(Primovist) and gadobenic acid (MultiHance) – will
remain available as these agents undergo hepatic
uptake, and can be used for imaging poorly
vascularised hepatic lesions, especially in delayed
phase imaging, that cannot be adequately studied with
other agents.
• Intra-articular formulations of the linear agent
gadopentetic acid (Magnevist) will continue to be
available because the dose of gadolinium that is
required for these scans is very low.
53. Information for healthcare
professionals
• All macrocyclic agents reviewed –
gadobutrol (Gadovist), gadoteric acid
(Dotarem) and gadoteridol (ProHance) –
will also remain available.
54. Information for healthcare
professionals
• Healthcare professionals should use
gadolinium contrast agents only when
essential diagnostic information
cannot be obtained with unenhanced
scans.
• Healthcare professionals should always
use the lowest dose that provides
sufficient enhancement for diagnosis.